Exelixis, Inc. (EXEL) Down 7.0% — Should I Pull Back Now?
Key Points
Exelixis, Inc. (EXEL) retreated sharply on Monday, falling 6.99% to close at $40.98 as sellers maintained firm control throughout the session. The stock shed $3.08 from its prior close of $44.06—a decisive single-session move that underscores the ongoing pressure on near-term momentum. The decline also pushed EXEL further from recent highs, leaving price action tilted to the downside with little sign of stabilization.
Selling pressure was accompanied by a notable uptick in trading activity. Volume reached 3,817,890 shares, well above the 90-day average of 2,777,213—a sign that the pullback drew heavier-than-usual participation. Stepping back further, EXEL now trades about 17.4% below its 52-week high of $49.62, reached on 06/23/2025, illustrating just how far shares have retreated from their peak. That distance from the high-water mark paints a picture of a market that has consistently chosen to sell into rallies rather than defend them.
Within the Health Care landscape, the magnitude of today's decline stood out. While peers such as Eli Lilly (LLY), Johnson & Johnson (JNJ), and Gilead Sciences (GILD) tend to trade with more measured day-to-day swings, EXEL's near-7% drop was a stark reminder that the stock is facing considerably more pressure than many of its sector counterparts.
Why Exelixis, Inc. Price is Moving Lower
Exelixis, Inc. came under fresh pressure after Royal Bank of Canada lowered its price target on March 2, 2026, trimming expectations from $46 to $43 while maintaining a "sector perform" stance. That downward revision in perceived upside helped catalyze a sharp 9.4% drop, further amplified by a Wall Street Zen downgrade from strong-buy the same day. With no new company-specific catalysts to offset the shift in tone, the selloff appears largely sentiment-driven—investors reassessing the stock's risk/reward profile as analysts grow more cautious about what the next leg higher might look like.
A persistent bearish overhang adds to the headwinds. Short interest climbed to roughly 27.9 million shares, representing about 11.0% of float and 11.8 days to cover—levels that tend to weigh on demand and make sustained rallies difficult to achieve. Although consensus estimates for FY2026 earnings have edged higher recently, to approximately $3.39 per share, the market is signaling that upward revisions alone may not be sufficient to support the stock in the near term. Quarterly revenue growth of 5.63% is encouraging, but it also reflects a more moderate growth trajectory that can invite valuation scrutiny in biotech, particularly when investor appetite shifts toward faster-growing names.
The broader analyst picture remains mixed, with opinion roughly split between buys and holds, and an average price target of around $47.17 that implies only modest upside—an increasingly unconvincing case following a wave of downgrades. Compared to Health Care heavyweights, Exelixis now faces a higher bar to demonstrate that it can sustain both growth and investor confidence. That combination typically keeps downside volatility elevated and warrants a measured approach.
What is the Exelixis, Inc. Rating - Should I Sell?
Weiss Ratings assigns EXEL a B rating with a current recommendation of Buy. Even so, investors would do well to maintain a degree of caution—Health Care stocks can pivot swiftly on clinical trial outcomes, competitive developments, and payer decisions, risks that don't always surface in a single quarter's fundamentals.
On its face, EXEL checks many quality boxes: it earns the Excellent Growth Index, the Excellent Efficiency Index, and the Excellent Solvency Index, underpinned by a 33.72% profit margin and a 35.53% ROE. The forward P/E of 15.88 may appear reasonable for Health Care, but valuation support alone offers little protection if sentiment sours or pipeline expectations disappoint. The Good Total Return Index and the Good Volatility Index likewise leave room for performance to lag steadier large-cap drugmakers during volatile stretches.
Peer comparisons reinforce the case for measured expectations. Within the Health Care sector, Eli Lilly and Company (LLY, B) and Johnson & Johnson (JNJ, B) carry matching B ratings, yet are generally regarded as more diversified businesses. Gilead Sciences, Inc. (GILD, B) also sits at B, while Amgen Inc. (AMGN, B-) and Vertex Pharmaceuticals Incorporated (VRTX, B-) rank marginally lower. EXEL's B rating places it among the stronger names in the group, though not decisively ahead on a risk-adjusted basis.
A B (Buy) rating points to a favorable overall risk/reward profile, yet this remains a stock where headline risk can quickly overshadow steady 5.63% revenue growth. Investors weighing a position in EXEL should carefully consider how much biotech-specific uncertainty they are prepared to absorb—even when the underlying indices appear solid.
About Exelixis, Inc.
Exelixis, Inc. (EXEL) is a Health Care company in the Pharmaceuticals, Biotechnology and Life Sciences industry, focused on discovering, developing, and commercializing oncology therapies. Its commercial presence is anchored by Cabometyx (cabozantinib), a small-molecule inhibitor approved across multiple cancer indications. The company also markets Cometriq, a separate cabozantinib formulation, and continues to build its business around targeted therapies designed to disrupt the pathways that fuel tumor growth and spread.
Despite its established standing in oncology drug development, Exelixis remains concentrated in a narrow set of marketed products—a profile that ties overall business performance closely to the sustained clinical and commercial relevance of cabozantinib. Beyond its current portfolio, the company is advancing a pipeline of investigational compounds, including antibody-drug conjugates (ADCs) and other targeted candidates, through a combination of internal research and external collaborations. While this model helps expand scientific reach and distribute development risk, Exelixis's long-term competitive position ultimately depends on its ability to move beyond its core backbone product and successfully bring additional pipeline programs to market.
Investor Outlook
Even with a Weiss Rating of B (Buy) providing a supportive backdrop, Exelixis, Inc. (EXEL) still warrants careful attention in the Health Care space. Investors should watch whether the recent pullback holds key chart levels and how quickly risk appetite across biotech shifts in either direction. It is equally important to monitor any erosion in the rating's underlying risk/reward drivers—particularly if volatility accelerates or balance-sheet concerns re-enter the conversation—since those developments can quickly undermine a Buy profile. For a full view of all B-rated Health Care stocks, see the complete rankings inside the Weiss Stock Screener.
--